Abstract

TEJERO HERNANDEZ, M. Angeles; GARCIA MARTINEZ, Elena; JOSE ARROYO MARIN, M  and  GOMEZ GUZMAN, Elena. Tolvaptan in a pediatric cardiorenal syndrome: What is its role?. Arch. argent. pediatr. [online]. 2018, vol.116, n.2, pp.e279-e282. ISSN 0325-0075.  http://dx.doi.org/10.5546/aap.2018.e279.

The cardiorenal syndrome has been defined as a situation in which therapy to relieve congestive symptoms of heart failure is limited by a decreased renal function. The resistance to conventional diuretic treatment makes difficult managing these patients. Tolvaptan, a selective vasopressin-2 receptor antagonist, has been used successfully in adults with this pathology but the experience with children is very limited. A five-year-old girl with renal failure waiting for a heart transplant is presented. Tolvaptan (0.1 mg/kg/day) was started at very low dosage, resulting in an excellent response. We analyzed the creatinine, urea, urine volume and sodium evolution. Renal function also improved. She could be discharged after four days of treatment (156 days of hospitalization) with ambulatory favourable follow-up until heart transplant. Tolvaptan should be considered in pediatric cases of conventional diuretic-resistant congestive heart failure, especially when complicated by kidney disease.

Keywords : Cardiorenal syndrome; Tolvaptan; Child.